Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
AIMS: Elevated non-fasting triglycerides mark elevated levels of remnant cholesterol. Using a Mendelian randomization approach, we tested whether genetically increased remnant cholesterol in hypertriglyceridaemia due to genetic variation in the apolipoprotein A5 gene (APOA5) associates with an increased risk of myocardial infarction (MI). METHODS AND RESULTS: We resequenced the core promoter and coding regions of APOA5 in individuals with the lowest 1% (n = 95) and highest 2% (n = 190) triglyceride levels in the Copenhagen City Heart Study (CCHS, n = 10 391). Genetic variants which differed in frequency between the two extreme triglyceride groups (c.-1131T > C, S19W, and c.*31C > T; P-value: 0.06 to <0.001), thus suggesting an effect on triglyceride levels, were genotyped in the Copenhagen General Population Study (CGPS), the CCHS, and the Copenhagen Ischemic Heart Disease Study (CIHDS), comprising a total of 5705 MI cases and 54 408 controls. Genotype combinations of these common variants associated with increases in non-fasting triglycerides and calculated remnant cholesterol of, respectively, up to 68% (1.10 mmol/L) and 56% (0.40 mmol/L) (P < 0.001), and with a corresponding odds ratio for MI of 1.87 (95% confidence interval: 1.25-2.81). Using APOA5 genotypes in instrumental variable analysis, the observational hazard ratio for a doubling in non-fasting triglycerides was 1.57 (1.32-2.68) compared with a causal genetic odds ratio of 1.94 (1.40-1.85) (P for comparison = 0.28). For calculated remnant cholesterol, the corresponding values were 1.67(1.38-2.02) observational and 2.23(1.48-3.35) causal (P for comparison = 0.21). CONCLUSION: These data are consistent with a causal association between elevated levels of remnant cholesterol in hypertriglyceridaemia and an increased risk of MI. Limitations include that remnants were not measured directly, and that APOA5 genetic variants may influence other lipoprotein parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [62]
In the citing paper
“Epidemiological and Mendelian randomization studies have also pointed toward a causal role of elevated triglycerides in atherosclerosis due to an elevation of remnant cholesterol particles (7-9).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Elevated triglycerides are associated with an increase in remnant cholesterol, a decrease in high-density lipoprotein cholesterol (HDL-C), and an increase in LDL particles with a change in morphology to small, dense particles.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Recent systematic studies comparing fasting and non-fasting samples have suggested that the difference is small for most lipid parameters [85,94-100].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [94]
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [76]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 1×
“Causal genetic estimates from instrumental variable analysis were compared with an observed risk of MI from observational epidemiology using the Altman and Bland method.(29)”
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Research works printed but not linked: 1
- 2001, Type III hyperlipoproteinemia (dyslipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 2835
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationNordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
“A necessity for triglyceride-rich lipoproteins to cause atherosclerosis and ASCVD is their ability to enter into the arterial intima, the location of the atherosclerotic plaque, leading ultimately to ASCVD.”
InfluentialSelf-citationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Self-citationGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationNational Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Varbo, A., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Circulation · doi:10.1161/circulationaha.113.003008 · Cited by 692
Self-citationHegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationMendelian randomization studies: a review of the approaches used and the quality of reporting
Boef, A. G. C., Dekkers, O. M., & le Cessie, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv071 · Cited by 610
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Estruch, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.008 · Cited by 540
“From the present data, it could be inferred that treatment of residual risk, measured as triglycerides or remnant-C, was probably more beneficial than further reducing LDL-C in high-risk subjects in primary prevention not eligible for statin treatment or already treated with moderate- or high-dose statins (8,15,28).”
BackgroundSaturated Fat Consumption and Risk of Coronary Heart Disease and Ischemic Stroke: A Science Update
Nettleton, J. A., Brouwer, I. A., Geleijnse, J. M., & Hornstra, G. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000455681 · Cited by 510
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: A primary prevention study
Quispe, R., Martin, S. S., Michos, E. D., Lamba, I., Blumenthal, R. S., Saeed, A., Lima, J., Puri, R., Nomura, S., Tsai, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab432 · Cited by 441
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Genetics of Coronary Artery Disease
McPherson, R., & Tybjaerg-Hansen, A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306566 · Cited by 371
Self-citationVirani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationHypertriglyceridemia and atherosclerosis
Peng, J., Luo, F., Ruan, G., Peng, R., & Li, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0625-0 · Cited by 245
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260
Varbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
“An alternative to directly measuring remnants is to calculate nonfasting remnant cholesterol levels as nonfasting total cholesterol minus HDL cholesterol minus LDL cholesterol, like it has been done in several studies of large Danish cohorts (Nordestgaard et al., 2007; Freiberg et al., 2008; Varbo et al., 2011a; Varbo…”
BackgroundResultSelf-citationWadström, B. N., Wulff, A. B., Pedersen, K. M., Jensen, G. B., & Nordestgaard, B. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab705 · Cited by 234
Self-citationManagement of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
Wolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231
Roeters van Lennep, J. E., Tokgözoğlu, L. S., Badimon, L., Dumanski, S. M., Gulati, M., Hess, C. N., Holven, K. B., Kavousi, M., Kayıkçıoğlu, M., Lutgens, E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad472 · Cited by 229
Self-citationLauridsen, B. K., Stender, S., Kristensen, T. S., Kofoed, K. F., Køber, L., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx662 · Cited by 213
Self-citationWadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac822 · Cited by 200
Self-citationRonit, A., Kirkegaard-Klitbo, D. M., Dohlmann, T. L., Lundgren, J., Sabin, C. A., Phillips, A. N., Nordestgaard, B. G., & Afzal, S. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313681 · Cited by 204
Self-citationMendelian randomization studies in coronary artery disease
Jansen, H., Samani, N. J., & Schunkert, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu208 · Cited by 212
Varbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.234146 · Cited by 209
Self-citationAssociation of rare and common variation in the lipoprotein lipase gene with coronary artery disease
Khera, A. V., Won, H.-H., Peloso, G. M., O’Dushlaine, C., Liu, D., Stitziel, N. O., Natarajan, P., Nomura, A., Emdin, C. A., Gupta, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.0972 · Cited by 198
“02 65 16 815 29 (22-42) 26 (17-38) Geisinger Health System DiscovEHR 6.”
InfluentialContribution of remnant cholesterol to cardiovascular risk
Langsted, A., Madsen, C. M., & Nordestgaard, B. G. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13059 · Cited by 189
Self-citationNew insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease
Budoff, M. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.004 · Cited by 184
Vallejo-Vaz, A. J., Fayyad, R., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J., Melamed, S., Barter, P., Waters, D. D., & Ray, K. K. (2018) · Circulation · doi:10.1161/circulationaha.117.032318 · Cited by 187
Varbo, A., & Nordestgaard, B. G. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab293 · Cited by 174
Self-citationKlempfner, R., Erez, A., Sagit, B.-Z., Goldenberg, I., Fisman, E., Kopel, E., Shlomo, N., Israel, A., & Tenenbaum, A. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002104 · Cited by 180
Joshi, P. H., Khokhar, A. A., Massaro, J. M., Lirette, S. T., Griswold, M. E., Martin, S. S., Blaha, M. J., Kulkarni, K. R., Correa, A., D'Agostino, R. B., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002765 · Cited by 177
“In a cohort of >50 000 Danish participants, Jorgensen et al identified genetic variants that contributed to extreme elevations in TG levels.(29) The investigators showed that these genetic elevations in calculated RLP-C based on nonfasting TG levels were associated with an 87% increased odds of MI.”
BackgroundBalling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.610 · Cited by 175
Self-citationLow nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study
Thomsen, M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.219881 · Cited by 171
Self-citationPechlaner, R., Tsimikas, S., Yin, X., Willeit, P., Baig, F., Santer, P., Oberhollenzer, F., Egger, G., Witztum, J. L., Alexander, V. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.065 · Cited by 171
Varbo, A., Benn, M., Smith, G. D., Timpson, N. J., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2015) · Circulation Research · doi:10.1161/circresaha.116.304846 · Cited by 171
Self-citationRecent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 164
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Bonicalzi, M.-È., Haince, J.-F., Droit, A., & Poirier, G. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4505-1 · Cited by 171
Hypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152
The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
Hu, X., Liu, Q., Guo, X., Wang, W., Yu, B., Liang, B., Zhou, Y., Dong, H., & Lin, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01554-0 · Cited by 150
Varbo, A., & Nordestgaard, B. G. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308305 · Cited by 157
Self-citationAdvances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 155
Self-citationGusarova, V., O’Dushlaine, C., Teslovich, T. M., Benotti, P. N., Mirshahi, T., Gottesman, O., Van Hout, C. V., Murray, M. F., Mahajan, A., Nielsen, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04611-z · Cited by 145
Self-citationBenn, M., & Nordestgaard, B. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy045 · Cited by 130
Self-citationVarbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.279463 · Cited by 133
Self-citationA Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease
Ahmad, O. S., Morris, J. A., Mujammami, M., Forgetta, V., Leong, A., Li, R., Turgeon, M., Greenwood, C. M. T., Thanassoulis, G., Meigs, J. B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8060 · Cited by 123
Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
Nordestgaard, L. T., Christoffersen, M., & Frikke‐Schmidt, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179777 · Cited by 141
Self-citationMatikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129
Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction
Doi, T., Langsted, A., & Nordestgaard, B. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.384 · Cited by 129
Self-citationElevated LDL Triglycerides and Atherosclerotic Risk
Balling, M., Afzal, S., Davey Smith, G., Varbo, A., Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.019 · Cited by 114
Self-citationThe association between triglycerides and incident cardiovascular disease: What is “optimal”?
Aberra, T., Peterson, E. D., Pagidipati, N. J., Mulder, H., Wojdyla, D. M., Philip, S., Granowitz, C., & Navar, A. M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.009 · Cited by 115
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124
Roychowdhury, T., Klarin, D., Levin, M. G., Spin, J. M., Rhee, Y. H., Deng, A., Headley, C. A., Tsao, N. L., Gellatly, C., Zuber, V., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01510-y · Cited by 105
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa172 · Cited by 122
Self-citationToth, P. P., Granowitz, C., Hull, M., Liassou, D., Anderson, A., & Philip, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008740 · Cited by 117
Triglycerides and risk of atherosclerotic cardiovascular disease: An update
Farnier, M., Zeller, M., Masson, D., & Cottin, Y. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.11.006 · Cited by 121
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Wulff, A. B., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310473 · Cited by 112
Self-citationOrringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103
Elshazly, M. B., Mani, P., Nissen, S., Brennan, D. M., Clark, D., Martin, S., Jones, S. R., Quispe, R., Donnellan, E., Nicholls, S. J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319887578 · Cited by 103
Cao, Y.-X., Zhang, H.-W., Jin, J.-L., Liu, H.-H., Zhang, Y., Gao, Y., Guo, Y.-L., Wu, N.-Q., Hua, Q., Li, Y.-F., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01076-7 · Cited by 98
Components of the Metabolic Syndrome and Risk of Type 2 Diabetes
Marott, S. C. W., Nordestgaard, B. G., Tybjærg-Hansen, A., & Benn, M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3777 · Cited by 96
Self-citationZanoni, P., Velagapudi, S., Yalcinkaya, M., Rohrer, L., & von Eckardstein, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.881 · Cited by 95
Lawlor, D. A., Nordestgaard, B. G., Benn, M., Zuccolo, L., Tybjaerg-Hansen, A., & Davey Smith, G. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht081 · Cited by 98
Self-citationWadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2023) · Diabetologia · doi:10.1007/s00125-023-06016-0 · Cited by 98
Self-citationWen, J., Huang, Y., Lu, Y., & Yuan, H. (2019) · Hypertension Research · doi:10.1038/s41440-019-0251-5 · Cited by 101
Wu, B., Pan, Y., Li, Z., Wang, J., Ji, S., Zhao, F., Chang, X., Qu, Y., Zhu, Y., Xie, L., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.107779 · Cited by 90
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Sniderman, A. D., Couture, P., Martin, S. S., DeGraaf, J., Lawler, P. R., Cromwell, W. C., Wilkins, J. T., & Thanassoulis, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082271 · Cited by 92
Triglyceride-rich lipoproteins and remnants: targets for therapy?
Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0745-6 · Cited by 90
The Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 105
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease
Rahman, M. S., Murphy, A. J., & Woollard, K. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.34 · Cited by 92
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 104
Triglycerides on the rise: should we swap seats on the seesaw?
Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu500 · Cited by 85
“genetic analyses indicate that higher concentrations of triglyceride and remnant lipoproteins contribute directly to the pathogenesis of ischaemic heart disease.(7,8) The cholesterol content of remnant”
Ruscica, M., Zimetti, F., Adorni, M. P., Sirtori, C. R., Lupo, M. G., & Ferri, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104653 · Cited by 82
Aguíar, C., Alegría, E., Bonadonna, R. C., Catapano, A. L., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(15)30001-5 · Cited by 90
Yang, X. H., Zhang, B. L., Cheng, Y., Fu, S. K., & Jin, H. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.012 · Cited by 78
Fu, L., Tai, S., Sun, J., Zhang, N., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2022) · Diabetes Care · doi:10.2337/dc21-2511 · Cited by 77
The burden of hypercholesterolemia and ischemic heart disease in an ageing world
Pirillo, A., & Norata, G. D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106814 · Cited by 75
Xu, J., Kitada, M., Ogura, Y., & Koya, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641852 · Cited by 79
Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state
White, K. T., Moorthy, M. V., Akinkuolie, A. O., Demler, O., Ridker, P. M., Cook, N. R., & Mora, S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.241752 · Cited by 74
Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes
D’Erasmo, L., Di Costanzo, A., Cassandra, F., Minicocci, I., Polito, L., Montali, A., Ceci, F., & Arca, M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313401 · Cited by 68
Arca, M., Veronesi, C., D’Erasmo, L., Borghi, C., Colivicchi, F., De Ferrari, G. M., Desideri, G., Pontremoli, R., Temporelli, P. L., Perrone, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015801 · Cited by 69
Kjeldsen, E. W., Thomassen, J. Q., & Frikke‐Schmidt, R. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159063 · Cited by 76
Self-citationChapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 67
Cui, G., Li, Z., Li, R., Huang, J., Wang, H., Zhang, L., Ding, H., & Wang, D. W. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.050 · Cited by 77
Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact
Guardiola, M., & Ribalta, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0665-y · Cited by 76
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-17
- Volume
- 34
- Issue
- 24
- Pages
- 1826-1833
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2040770080
- Cited by
- 501
- References
- 60
- Citations by year
- 2026: 28 · 2025: 53 · 2024: 48 · 2023: 40 · 2022: 51 · 2021: 45 · 2020: 41 · 2019: 39 · 2018: 26 · 2017: 34 · 2016: 31 · 2015: 30 · 2014: 20 · 2013: 11
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- remnant cholesterol, hypertriglyceridemia, myocardial infarction, APOA5, genetic variants, causal risk factors, remnant lipoproteins, Copenhagen City Heart Study, Copenhagen General Population Study, instrumental variables, Mendelian randomization
- MeSH terms
- Apolipoprotein A-V, Adult, Aged, Aged, 80 and over, Apolipoproteins A, Cholesterol, Female, Genotype, Humans, Lipoproteins, Male, Middle Aged, Myocardial Infarction, Promoter Regions, Genetic, Prospective Studies, Risk Factors, Triglycerides, Hypertriglyceridemia, Linkage Disequilibrium, Case-Control Studies, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.